McKesson projects $32.55-$32.95 adjusted EPS for FY25
McKesson Corporation Reports Fiscal 2025 Third Quarter Results and Raises Full Year Adjusted EPS Guidance
McKesson Corporation (NYSE: MCK) has released its fiscal 2025 third quarter financial results. Results can be accessed on McKesson’s Investor Relations website at investor.mckesson.com/financials/quarterly-results.
McKesson raises, narrows FY25 adjusted EPS view to $32.55-$32.95 from $32.40-$33
Based on our third quarter performance, we are raising and narrowing our guidance range for fiscal 2025 Adjusted Earnings per Diluted Share to $32.55 to $32.95. We are also pleased to announce the signing of a definitive agreement to acquire a controlling interest in PRISM Vision Holdings,
Drug distributor McKesson missed estimates for third-quarter revenue on Wednesday, hurt by less-than-expected sales in its ...
Welcome to McKesson's third quarter fiscal 2025 earnings conference call. Please be advised that today's conference is being ...
After the purchase concludes, the firm intends to include PRISM Vision into its U.S. Pharmaceutical division subject to ...
McKesson inked a deal to buy a controlling interest in Prism Vision Holdings, as it also logged higher profit and revenue in its fiscal third quarter. The drug distributor said Wednesday that it ...
Reports Q3 revenue $95.3B, consensus $95.86B. “McKesson (MCK) reported strong third quarter operational results with broad-based Revenue growth ...
Irving-based McKesson (NYSE: MCK) announced on Feb. 4 an agreement to buy an 80% controlling interest in New Providence, New ...
IRVING, Texas (AP) — IRVING, Texas (AP) — McKesson Corp. (MCK) on Wednesday reported fiscal third-quarter earnings of $879 million. The Irving, Texas-based company said it had profit of $6.95 per ...
McKesson Corp (MCK) reports an 18% revenue increase and raises EPS guidance amid strategic investments and acquisitions.
Welcome to McKesson's Third Quarter Fiscal 2025 Earnings Conference Call. Please be advised that today's conference is being recorded. At this time, I'd like to turn the conference over to Rachel ...
McKesson Corp. and AmerisourceBergen Drug Corp. are among the drug distributors that won a bid to toss antitrust claims that they colluded to inflate prices of several generic pharmaceutical products.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback